Why the study?
The 2015 European pulmonary hypertension guidelines recommend a risk stratification strategy for pulmonary arterial hypertension, but its validation and potential prognostic information needed investigation.
Does the 2015 ESC risk assessment tool accurately predict mortality in Chinese patients with idiopathic pulmonary arterial hypertension?
Does the 2015 ESC risk assessment tool accurately predict mortality in Chinese patients with idiopathic pulmonary arterial hypertension?
The 2015 ESC risk stratification tool and its simplified version effectively discriminate risk groups and predict mortality in Chinese patients with idiopathic pulmonary arterial hypertension.
Background: The 2015 European pulmonary hypertension guidelines recommend a risk stratification strategy for pulmonary arterial hypertension (PAH). We aimed to investigate the validation and potential prognostic information in our patients. Methods: The risk assessment variables proposed by the PH guidelines was performed, using World Health Organization function class, 6-min walking distance, brain natriuretic peptide or its N-terminal fragment, right arterial pressure, cardiac index, mixed venous saturation, right atrium area, pericardial effusion, peak oxygen consumption and ventilatory equivalents for carbon dioxide. An abbreviated version also was applied. Results: The 392 patients were enrolled between 2009 and 2018. After a median interval of 13 months, re-evaluation assessments were available for 386 subjects. The PH guidelines risk tool may effectively discriminate three risk group and mortality (p< 0.001) both at baseline and re-evaluation. Meanwhile, its simplified risk version was valid for baseline and accurately predicted the risk of death in all risk group (p< 0.001). At the time of re-evaluation, the percentage of low risk group has an increase, but a greater proportion achieved high risk group and a lesser proportion maintained in intermediate risk group. Conclusions: The 2015 European PH guidelines and its simplified version risk stratification assessment present effective discrimination of different risk groups and accurate mortality estimates in patients with IPAH. Changes of risk proportion at re-evaluation implicated that natural treatment decisions may not be consistently with goal-oriented treatment strategy.
No takes yet. Share an insight, caveat, or question.
Gong et al. (2020) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: